Response In Multiple Sclerosis Patients Research Articles

Serological response of multiple sclerosis patients and controls to 6/94-parainfluenza virus.

The serological responses of 195 multiple sclerosis (MS) patients and 251 controls were tested against 6/94-parainfluenza virus, which was previously isolated from brain tissue of two patients with MS. The hemagglutination-inhibition titers of greater than or equal to 1: 128 were found more frequently in MS patients (21.5%) than in controls (14.0%). However, the geometric mean titers did not differ between these two groups. The present study concludes that a causal relationship of 6/94-virus to MS, based on a specific immune response, is improbable, although it does not exclude the possibility of a pathogenetic significance of the agent in the cases from which the autopsy material was derived.

Detection of Cellular Hypersensitivity among Multiple Sclerosis (MS) Patients to 6/94 Virus; a Parainfluenza Type 1 Isolate from MS Brain Tissue

Multiple sclerosis (MS) patients and normal subjects were tested for cellular hypersensitivity, using the leukocyte migration inhibition test LMI), to a parainfluenza-1-virus (6/94), previously isolated from brain biopsy tissue of an MS patient. The response of MS patients as a group was not greater than that of normals to 6/94, but a significant increase in the response was observed among selected patients in the early active and chronic advanced stages of the disease. MS patients, however, did not differ from normal subjects in their cell response to Sendai virus, a similar parainfluenza type 1 virion used for comparison.

Somatosensory evoked responses in multiple sclerosis patients with varying sensory loss.

Somatosensory evoked responses in multiple sclerosis patients with varying sensory loss.

NEW YORK NEUROLOGICAL SOCIETY AND NEW YORK ACADEMY OF MEDICINE, SECTION OF NEUROLOGY AND PSYCHIATRY

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue